<DOC>
	<DOCNO>NCT00583596</DOCNO>
	<brief_summary>AGA-004 - The objective study determine safety , effectiveness clinical utility AMPLATZER Duct Occluder patient patent ductus arteriosus . AGA-007 - The objective study evaluate long term safety effectiveness issue may adequately address AGA-004 .</brief_summary>
	<brief_title>Closure Of Patent Ductus Arteriosus With AMPLATZER Duct Occluder AMPLATZER® Duct Occluder</brief_title>
	<detailed_description />
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<criteria>Patients demonstrate patent ductus arteriosus Body weight &gt; 5 Kilograms Pulmonary vascular resistance 8 Woods unit Rp/Rs &gt; 0.4 . Additional cardiac noncardiac abnormality reasonably expect significantly affect patient 's health adversely next two year , i.e . : cancer , Eisenmenger 's syndrome , serious congenital heart disease . Pelvic vein inferior vena cava thrombosis Sepsis ( local/generalized ) type infection successfully treat prior device placement . History repeat pulmonary infection Demonstrated intracardiac thrombus echocardiography • Inability obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>patent ductus arteriosus ( PDA )</keyword>
</DOC>